Incyte Corp INCYTE ORD SHS
Incyte Corp INCYTE ORD SHS/ US45337C1027 /
0J9P
|
04.01.2024 00:00:00
|
Zm.
-
|
Wolumen |
Bid06:00:04 |
Ask06:00:04 |
Kapitalizacja Rynkowa |
St. dywidendy |
Wskaźnik C/Z |
|
65,51USD
|
-
|
47
Obrót: - |
-Wolumen Bid: - |
-Wolumen Ask: - |
16,06 mldUSD |
- |
31,23 |
Opis działalności
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics.
Zarząd & Rada nadzorcza
| CEO |
| Hervé Hoppenot |
| Zarząd |
| Christiana Stamoulis, Paula J. Swain, Pablo J. Cagnoni, Steven H. Stein, M.D., Maria E. Pasquale, Dr. Lothar H. Finke, Barry P. Flannelly, Denise Brashear, Vijay Iyengar, M.D., Jonathan E. Dickinson, Michael Morrissey, Xiaozhao Wang |
| Rada nadzorcza |
| Hervé Hoppenot, Julian C. Baker, Jean-Jacques Bienaimé, Otis Brawley, M.D., Paul J. Clancy, Dr. Jacqualyn A. Fouse, Edmund P. Harrigan, M.D., Katherine High, M.D., Susanne Schaffert |
Dane firmy
| Nazwa: |
Incyte Corporation |
| Adres: |
1801 Augustine Cut-Off,Wilmington, DE 19803, USA |
| Telefon: |
+1-302-498-6700 |
| Fax: |
- |
| E-mail: |
-
|
| Internet: |
www.incyte.com/ |
| Przemysł: |
Biotechnologia |
| Sektor: |
Biotechnologia |
| Podsektor: |
Biotechnologia |
| Koniec roku finansowego: |
31.12 |
| Free float: |
41,80% |
| Data IPO: |
- |
Relacje inwestorskie
| Nazwa: |
Ben Strain |
| Telefon: |
+1-302-274-4779 |
| Fax: |
- |
| E-mail: |
IR@incyte.com
|
Główni akcjonariusze
| Inne |
|
42,84% |
| BAKER BROS ADVISORS LP |
|
16,11% |
| BlackRock Inc. |
|
10,82% |
| Vanguard Group |
|
10,02% |
| Dodge & Cox |
|
7,16% |
| State Street Corporation |
|
4,50% |
| RENAISSANCE TECHNOLOGIES LLC |
|
2,47% |
| GEODE CAPITAL MANAGEMENT LLC |
|
1,90% |
| Morgan Stanley |
|
1,49% |
| Inne |
|
2,69% |
